NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Study summary

The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNBTXR3 and SABR

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 24, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?13 U.S. locations

Locations may change over time.

Who runs it?Nanobiotix

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Nanobiotix
Interventions being studied: Drug: NBTXR3; Radiation: SABR; Drug: Nivolumab; Drug: Pembrolizumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Treatment approach

Immunotherapy→Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Signed informed consent form
Biopsy-confirmed cancer diagnosis indicated to receive anti-PD-1 therapy: Dose Escalation: 1. Escalation Cohort 1: Is inoperable LRR with tumor in previously irradiated HN field that is amenable to re-irradiation or R/M HNSCC with tumor in previously irradiated HN field that is amenable to re-irradiation, or 2. Escalation Cohort 2: Has metastasized to the lung (including involved lymph nodes) with tumor in a previously non-irradiated lung field, or 3. Escalation Cohort 3: Has metastasized to the liver with tumor in a previously non-irradiated liver field Expansion: 1. Expansion Cohorts 1 and 2: Is inoperable LRR or R/M HNSCC with at least one lesion that is amenable to irradiation within head and neck region, lung or liver 2. Expansion Cohort 3: Is inoperable NSCLC, malignant melanoma, HCC, RCC, urothelial cancer, cervical cancer, TNBC that has metastasized to soft tissues, lung (including mediastinal lymph nodes) or liver with at least one lesion that is amenable to irradiation
Prior anti-PD-1 exposure as follows: Dose Escalation (all cohorts): 1. Has not received prior anti-PD-1 therapy (i.e., anti-PD-1 naïve), or 2. Has received prior anti-PD-1 therapy and meets criteria consistent with anti-PD-1 primary resistance (i.e., primary anti-PD-1 non-responder), or 3. Has received prior anti-PD-1 therapy and meets criteria consistent with anti-PD-1 secondary resistance (i.e., secondary anti-PD-1 non-responder) Expansion: 1. Expansion Cohorts 1 and 3: Has received prior anti-PD-1 therapy and meets criteria consistent with anti-PD-1 primary or secondary resistance as described above 2. Expansion Cohort 2: Has not received prior anti-PD-1 therapy (i.e., anti-PD-1 naïve)
Has at least one tumor lesion that can be accurately measured according to RECIST 1.1. and is amenable for intratumoral injection
ECOG performance status 0-2
Life expectancy \>12 weeks
Adequate organ and bone marrow function
Negative pregnancy test ≤ 7 days prior to NBTXR3 injection in all female participants of child-bearing potential

Reasons someone may not be able to joinExclusion criteria

History of immune-related adverse events related to administration of anti-PD-1/L1 that led to the termination of the previous anti-PD-1 therapy due to intolerance or toxicity and precludes further PD-1 exposure
Symptomatic central nervous system metastases and/or carcinomatous meningitis
Active autoimmune disease that has required systemic treatment in the past 1 year
Known HIV or active hepatitis B/C infection
Active infection requiring intravenous treatment with antibiotics
Received a live virus vaccine within 30 days prior to study treatment
History of pneumonitis that required steroids or with current pneumonitis
Extensive metastatic disease burden defined as more than 5 lesions overall including the primary tumor
Locoregional recurrent HNSCC with ulceration
Has received prior therapy with a checkpoint inhibitor, within 2 weeks prior to NBTXR3 injection
Has received prior systemic anti-neoplastic therapy, including investigational agents, within 4 weeks prior to NBTXR3 injection
Has not recovered from AEs due to previous anti-neoplastic therapies and/or interventions (including radiation) to ≤ Grade 1 or baseline at screening
Clinically significant cardiac arrhythmias
Class III or IV Congestive Heart Failure as defined by the New York Heart Association functional classification system \< 6 months prior to screening
A pregnant or nursing female, or women of child-bearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
Any condition for which participation would not be in the best interest of the participant

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of California San FranciscoSan Francisco, California
Moffitt Cancer CenterTampa, Florida
Emory UniversityAtlanta, Georgia
University of Chicago Medical CenterChicago, Illinois
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland
Karmanos Cancer InstituteDetroit, Michigan
Henry Ford Cancer InstituteDetroit, Michigan
Christus St. Vincent Regional Cancer CenterSanta Fe, New Mexico
Northwell HealthManhasset, New York
University of North Carolina, School of MedicineChapel Hill, North Carolina
Gabrail Cancer CenterCanton, Ohio
St Luke's University Health NetworkBethlehem, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 24, 2025. Always confirm current availability with the study team.

View original record ↗